Daclizumab (Zinbryta), the anti-CD25 monoclonal antibody approved for the treatment of relapsing MS in May 2016 (December 2016 in Canada), has been voluntarily withdrawn by its manufacturers and will no longer be available. The withdrawal was announced on March 2, in a press release issued by Biogen and AbbVie (www.businesswire.com/news/home/20180302005168/en/Biogen%C2%A0and-AbbVie-Announce%C2%A0the-Voluntary%C2%A0Worldwide-Withdrawal-Marketing-Authorizations). Read More
Latest News
DMF: the Canadian MS patient experience
February 28, 2018A majority of MS patients currently treated with dimethyl fumarate (DMF) state that their therapy is as easily tolerated as other disease-modifying therapies, according to the results of a recent online survey. The survey was conducted in December 2017-February 2018 on MSology, the sister site of NeuroSens. MSology provides news and resources to MS patients, and attracts about 35,000 visitors per year (www.msology.com). Read More
Third failed trial for solanezumab in AD
February 22, 2018Solanezumab does not appear to slow cognitive decline in patients with mild Alzheimer’s disease, according to the newly-published results of the EXPEDITION-3 trial (Honig et al. N Engl J Med 2018;378:321-330). Prior studies also failed to show a benefit. Read More
Comorbidity – a publishing phenomenon
February 14, 20182018Research into comorbidity has expanded exponentially in recent years, with over 55,000 papers published in the medical literature over the past seven years, according to a new analysis of the Web of Science database of biomedical publications (Catala-Lopez et al. PLoS One 2018;13:e0189091). The literature search terms included “comorbidity”, in which there is another medical condition in addition to an index disease; as well as the emerging “multimorbidity”, a more patient-centric term in which no index disease is defined and all conditions are viewed with equal importance. Several neologisms have been coined less successfully, such as “multipathology”, “polymorbidity”, “polipathology”, and “pluripathology”. Read More